Navigation Links
Labopharm appeals FDA's decision on once-daily tramadol
Date:10/15/2007

LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has initiated the U.S. Food and Drug Administration (FDA)'s Formal Dispute Resolution process, appealing the Agency's decision regarding the Company's once-daily formulation of tramadol. Labopharm received a second Approvable Letter from the FDA for its once-daily formulation of tramadol in May of this year. The Company firmly believes it has met the statutory standards for approval of its once-daily tramadol formulation.

About the FDA's Formal Dispute Resolution Process

FDA regulations provide a mechanism for those seeking regulatory approval of a drug product through a New Drug Application (NDA) to obtain formal review of any Agency decision through a Formal Dispute Resolution process by raising the matter with the supervisor of the employee who made the decision. If the issue is not resolved at the primary supervisory level, the applicant may request that the matter be reviewed at the next higher supervisory level. This process may continue through the Agency's chain of command, through the Centers to the Commissioner of Food and Drugs. The Formal Dispute Resolution process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, new drug review, generic drug review, and post-marketing oversight processes.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company wit
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kalam Appeals to Eradicate Hearing Disability
2. UNAIDS Chief Appeals for Projects to Battle AIDS/HIV
3. Man Appeals to President to Save His Ailing Son
4. Appeals Against The New Resolution By NICE Increases
5. Unicef Appeals To Prioritize Children In Fight Against AIDs
6. Swiss Group Appeals Invocation of Euthanasia Option For The Severely Depressed
7. Fidel Castro Appeals for Investment in Health Rather Than in Arms
8. FDAs Failure Urges It to Reassess Its Policies
9. FDAs Gesture for Firm Manufacturing Drug for Cushings Syndrome
10. People suffering from Alzheimer’s: can they take decisions about their treatment
11. Decision making made easier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015 The PracticeMatch Career Fair ... 8:00 pm at the Sheraton Colonial Boston North Hotel, 1 ... and groups with career opportunities will be attending from across ... free hors d’oeuvres and raffle prize drawings. , Leslie Thompson, ... is an ideal location to hold a career fair. In ...
(Date:4/28/2015)... April 28, 2015 The Awareness Counselor team ... common topic of judging. According to Awareness Counselor, there are ... when directed outward, and to an individual who self-judges. This ... clients as a class or one one one talk. , ... of Awareness Counselor, is that every being on earth is ...
(Date:4/28/2015)... Aliso Viejo, CA (PRWEB) April 28, 2015 ... created for use in Final Cut Pro X ... attention to specific areas on-screen with classic buttons, animated ... Annotate is the perfect compliment to vlogs, video series, ... Cut Pro X 10.2 or newer. ProTube Annotate ...
(Date:4/28/2015)... PREVENT Life Safety, Inc., America’s premier provider ... their Southern California offices from Orange, California to Rancho ... I (letter I), Rancho Cucamonga, CA, 91730, is effective ... the significant growth the company has realized in the ... to provide superior life safety services, including fire damper ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 3Health News:FCPX plugin developer Pixel Film Studios releases Protube Annotate plugin for Final Cut Pro X. 2Health News:PREVENT Life Safety Moves to New Office in Rancho Cucamonga 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4
... smokers twice as likely to have strokes, they are almost ... to a study presented today at the Canadian Stroke Congress. ... stroke patients (264 smokers and 718 non-smokers) at an Ottawa ... who smoked was 58, compared to age 67 for non-smokers. ...
... in South Africa and Brazil become happier as they age. ... a developing country can significantly improve the wellbeing of its ... older people in South Africa and Brazil improved between 2002 ... enlightened social policies, according to a study from the New ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... United States, which reached a record high last year, are ... So far this year, some 200 drug shortages have ... Jensen, associate director of the Drug Shortage Program within the ...
... using a 320 detector row CT scanner found that a ... sufficient enhancement in more than 96% of coronary segments," said ... and one of the authors of the study. ... equal to 80 milliliters of iopamidol," he said. The ...
... such as depression, obsessive-compulsive disorder or anxiety states ... of the neurotransmitter serotonin. Neurotransmitters are compounds that ... endings and activate the firing of neighboring neurons. ... transmission of nerve impulses. The serotonin transporter (SERT) ...
... women experience peer pressure to share sexual images via the ... Melbourne study has found. ,Sexting, is the practice of ... The study is one of the first academic investigations ... findings were presented to the 2011 Australasian Sexual Health Conference ...
Cached Medicine News:Health News:Smoking causes stroke to occur 2Health News:Older people are happier in Brazil and South Africa 2Health News:Drug Shortages Even Worse This Year: FDA 2Health News:Combating mood disorders 2Health News:'Sexting' driven by peer pressure 2
(Date:4/28/2015)... and INDIANAPOLIS , April 28, 2015 /PRNewswire/ ... procedure and receive a heart stent are prescribed an oral ... attack, a blood clot in their heart stent (stent thrombosis), ... Poll found that 52 percent of 275 ACS patients who ... the way they take their prescribed OAP therapy, even though ...
(Date:4/28/2015)... We are living a connected life in a ... and very soon we will be able to connect our ... life market has been valued by Frost & Sullivan at ... drive and manage this change to stay ahead of the ... Highlights of the congress include a groundbreaking keynote address showcasing ...
(Date:4/27/2015)... April 27, 2015 A  study published today ... and presented at the annual Pediatric Academic Societies ... of rapid whole-genome sequencing in neonatal and pediatric intensive ... STAT-Seq test helped diagnose a genetic disease in more ... compared to just nine percent with standard genetic tests. ...
Breaking Medicine Technology:Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 2Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 3Study Demonstrates Potential Of Rapid Whole-Genome Sequencing In Critically Ill Infants 2Study Demonstrates Potential Of Rapid Whole-Genome Sequencing In Critically Ill Infants 3
... 2011 Merz Pharmaceuticals today announced the launch of ... their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum ... approved by the U.S. Food and Drug Administration (FDA) ... decrease the severity of abnormal head position and neck ...
... HILLS, Ill., March 8, 2011 Genus Oncology, LLC, a ... cancer, announced it has received an Orphan Drug Designation from ... 1 (MUC1) targeting peptide, GO-203-2c, for the treatment of pancreatic ... the US Orphan Drug Act, is for a product that ...
Cached Medicine Technology:Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 2Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 3Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 4Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 5Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 6Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer 2
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Medicine Products: